Surrozen Inc. is a company pioneering targeted therapeutics which selectively activates the Wnt pathway for tissue repair and regeneration. Surrozen Inc., formerly known as Consonance-HFW Acquisition Corp., is based in SOUTH SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | $3.48M |
| Net Income (Most Recent Fiscal Year) | $-242.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 24.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2885.33% |
| Net Margin (Trailing 12 Months) | -2885.33% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -93.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.14 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-18.83 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $-8.57 |
| Diluted Earnings per Share (Trailing 12 Months) | $-40.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.61M |
| Free Float | 7.92M |
| Market Capitalization | $278.77M |
| Average Volume (Last 20 Days) | 0.28M |
| Beta (Past 60 Months) | 0.52 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.74% |
| Percentage Held By Institutions (Latest 13F Reports) | 66.57% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |